- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00534430
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation before a donor stem cell transplant or a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying the side effects and best way to give busulfan together with etoposide and total-body irradiation and to see how well they work in treating patients who are undergoing a donor stem cell or bone marrow transplant for advanced hematologic cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To determine the efficacy of a preparative regimen comprising dose targeted busulfan, etoposide, and fractionated total-body irradiation followed by allogeneic hematopoietic stem cell or bone marrow transplantation in patients with advanced hematologic malignancies.
- To determine the efficacy of this regimen in patients with acute myeloid leukemia in first remission with unfavorable cytogenetics.
- To evaluate the early and late toxicities of this regimen.
OUTLINE:
- Preparative chemotherapy regimen: Patients receive busulfan IV over 2 hours once every 6 hours on days -14 to -8 for a total of 16 doses and etoposide IV on day -3.* NOTE: *Patients also receive oral or IV dilantin 1-3 times daily on days -18 to -5 for prophylaxis of grand mal seizures.
- Fractionated total-body irradiation (FTBI): Patients undergo FTBI on days -7 to -4 for a total of 10 fractions.
- Allogeneic transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.
- Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV or orally on days -1 to 50 followed by a taper to day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil orally or IV over 2 hours twice daily on days 0-27, followed by a taper until day 56.
After completion of study treatment, patients are followed annually for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
Acute myeloid leukemia (AML)
- Failed remission induction therapy or in relapse beyond second remission
- In first remission with poor risk cytogenetics (e.g., 11q abnormalities, -7, -5, complex abnormalities [i.e., > 3 abnormalities, 6;9 translocation and 3q abnormalities del (7q), del (5q), complex abnormalities ≥ abnormalities, 9q, 20q, 21q, 17q, t(9;21)])
Acute lymphoblastic leukemia (ALL)
- Failed remission induction therapy or in relapse beyond second remission
- Blastic phase chronic myelogenous leukemia
- Refractory anemia with excess blasts
- Refractory anemia with excess blasts in transformation
- HLA -A, -B, -C, -DR identical sibling donor match available
- No relapse after prior bone marrow transplantation
PATIENT CHARACTERISTICS:
- Cardiac ejection fraction ≥ 50%
- Serum creatinine ≤ 1.2 times upper limit of normal (ULN) or creatinine clearance > 80 mL/min
- Bilirubin ≤ 1.5 times ULN
- AST and ALT < 5 times ULN
- FEV_1 ≥ 50% of predicted normal
- DLCO ≥ 50% of predicted normal
- No psychological or medical condition that would preclude allogeneic transplantation (in the opinion of the treating physician)
- Not pregnant
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 28 days since prior induction or reinduction therapy
- Prior etoposide and busulfan allowed
- No prior radiation therapy that would exclude total-body irradiation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Busulfan, FTBI and VP16
IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival at 5 Years Post-Transplant.
Time Frame: Date of Transplant to Five Years post-Transplant
|
Kaplan-Meier estimate of an event of death estimated at five years post-transplant.
95% confidence intervals were calculated from the logit transform of the Greenwood variance.
The transformation was necessary to keep the estimate within the probability space of 0 to 100%.
|
Date of Transplant to Five Years post-Transplant
|
Disease-free Survival at Five Years Post-transplant
Time Frame: Date of transplant to five years post-transplant
|
Kaplan-Meier estimate of an event of relapse or death estimated at five years post-transplant.
95% confidence intervals were calculated from the logit transform of the Greenwood variance.
The transformation was necessary to keep the estimate within the probability space of 0 to 100%.
|
Date of transplant to five years post-transplant
|
Overall Survival Comparing Diagnosis Groups
Time Frame: Date of Transplant to Five Years post-Transplant
|
Kaplan-Meier estimate of an event of death estimated at five years post-transplant.
95% confidence intervals were calculated from the logit transform of the Greenwood variance.
The transformation was necessary to keep the estimate within the probability space of 0 to 100%.
|
Date of Transplant to Five Years post-Transplant
|
Cumulative Incidence of Relapse With Transplant-related Death as the Competing Risk: Diagnosis Groups Are Compared.
Time Frame: Date of Transplant to Five Years post-Transplant. Estimate is at Five Years post-Transplant.
|
Fine and Gray estimate of cumulative incidence of Relapse, with Death as the competing risk.
Estimate is at five years post-transplant.
Ninety-five percent confidence interval is by logit transformation of Greenwood variance to keep the interval within the probability space of 0% to 100%.
|
Date of Transplant to Five Years post-Transplant. Estimate is at Five Years post-Transplant.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Early and late toxicities
Time Frame: 30 days, 31-100 days, 101 to 365 days and yearly through 5 years post transplant
|
30 days, 31-100 days, 101 to 365 days and yearly through 5 years post transplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Anthony S. Stein, MD, City of Hope Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- refractory anemia with excess blasts
- refractory anemia with excess blasts in transformation
- previously treated myelodysplastic syndromes
- secondary myelodysplastic syndromes
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- recurrent adult acute myeloid leukemia
- adult acute myeloid leukemia in remission
- blastic phase chronic myelogenous leukemia
- recurrent adult acute lymphoblastic leukemia
- recurrent childhood acute lymphoblastic leukemia
- recurrent childhood acute myeloid leukemia
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Leukemia
- Preleukemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Etoposide
- Mycophenolic Acid
- Busulfan
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- 99041
- P30CA033572 (U.S. NIH Grant/Contract)
- CHNMC-99041
- CDR0000564777 (Registry Identifier: NCI PDQ)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on etoposide
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...UnitedHealthcareActive, not recruitingSmall Cell Lung CancerUnited States
-
University Hospital, BonnCompletedEpendymomas | Recurrent Brain Tumors | Supratentorial PNETs | MedulloblastomasGermany
-
Sun Yat-sen UniversityRecruitingSmall Cell Lung CarcinomaChina
-
Guizhou Medical UniversityUnknownSmall-cell Lung CancerChina
-
Third Military Medical UniversityUnknownExtensive-stage Small Cell Lung Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Enrolling by invitation
-
CephalonWithdrawn
-
Qingdao UniversityUnknownProgression Free SurvivalChina
-
Annick DesjardinsAstraZenecaCompletedGlioblastoma | GliosarcomaUnited States
-
Shanghai Henlius BiotechRecruitingExtensive Stage Small Cell Lung CancerUnited States